NK Cell Subsets Changes in Partial Remission and Early Stages of Pediatric Type 1 Diabetes.
Adolescent
Age Factors
Biomarkers
/ metabolism
CD56 Antigen
/ metabolism
Case-Control Studies
Child
Child, Preschool
Diabetes Mellitus, Type 1
/ diagnosis
Disease Progression
Female
Flow Cytometry
GPI-Linked Proteins
/ metabolism
Humans
Immunophenotyping
Killer Cells, Natural
/ immunology
Longitudinal Studies
Male
Pancreas
/ immunology
Phenotype
Pilot Projects
Receptors, IgG
/ metabolism
Remission Induction
Time Factors
Treatment Outcome
NK cell subpopulations
autoimmunity
partial remission
pediatrics
type 1 diabetes
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
09
2020
accepted:
04
12
2020
entrez:
11
2
2021
pubmed:
12
2
2021
medline:
23
6
2021
Statut:
epublish
Résumé
Type 1 diabetes (T1D) is a chronic metabolic disease characterized by the autoimmune destruction of β-cells in the pancreatic islets. T1D is preceded by islet-specific inflammation led by several immune cells. Among them, natural killer (NK) cells are emerging as important players in T1D development. Human NK cells are characterized by CD56 and CD16 expression, which allows classifying NK cells into four subsets: 1) CD56
Identifiants
pubmed: 33569058
doi: 10.3389/fimmu.2020.611522
pmc: PMC7869615
doi:
Substances chimiques
Biomarkers
0
CD56 Antigen
0
FCGR3B protein, human
0
GPI-Linked Proteins
0
NCAM1 protein, human
0
Receptors, IgG
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
611522Informations de copyright
Copyright © 2021 Gomez-Muñoz, Perna-Barrull, Villalba, Rodriguez-Fernandez, Ampudia, Teniente-Serra, Vazquez, Murillo, Perez, Corripio, Bel and Vives-Pi.
Déclaration de conflit d'intérêts
MV-P holds a patent that relates to immunotherapy for T1D and is co-founder of Ahead Therapeutics S.L. SR-F is part-time employed at Ahead Therapeutics S.L. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Exp Immunol. 2016 Jan;183(1):1-7
pubmed: 25989477
N Engl J Med. 1985 Aug 8;313(6):353-60
pubmed: 3159965
JAMA. 2016 Mar 15;315(11):1107-8
pubmed: 26978201
Leukemia. 2005 May;19(5):835-40
pubmed: 15744340
Immunity. 2003 Jan;18(1):41-51
pubmed: 12530974
Nat Immunol. 2010 Feb;11(2):121-8
pubmed: 20023661
Discov Med. 2011 Jun;11(61):513-20
pubmed: 21712017
Front Immunol. 2019 May 03;10:982
pubmed: 31130961
Immunology. 2009 Apr;126(4):458-65
pubmed: 19278419
Int J Mol Sci. 2020 Jan 11;21(2):
pubmed: 31940853
Transl Res. 2019 Aug;210:8-25
pubmed: 30953609
Clin Exp Immunol. 2017 Mar;187(3):418-427
pubmed: 27783386
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5115-20
pubmed: 17360338
Horm Res Paediatr. 2017;88(5):307-315
pubmed: 28772271
Clin Exp Immunol. 2008 Mar;151(3):467-75
pubmed: 18190608
Autoimmun Rev. 2008 May;7(5):384-90
pubmed: 18486926
Front Immunol. 2018 Aug 13;9:1869
pubmed: 30150991
Oncoimmunology. 2017 Aug 10;6(9):e1342024
pubmed: 28932646
Diabetes. 2011 Mar;60(3):857-66
pubmed: 21270236
Haematologica. 2015 Apr;100(4):489-98
pubmed: 25596273
Pediatr Diabetes. 2014 Nov;15(7):469-76
pubmed: 25287319
J Immunol. 2010 Mar 1;184(5):2272-80
pubmed: 20130214
Immunity. 2018 Nov 20;49(5):971-986.e5
pubmed: 30413361
Curr Diab Rep. 2016 Nov;16(11):109
pubmed: 27664042
Blood Adv. 2020 Apr 14;4(7):1388-1406
pubmed: 32271902
Proc Natl Acad Sci U S A. 2004 May 25;101(21):8102-7
pubmed: 15141080
Diabetes. 2007 Jan;56(1):177-85
pubmed: 17192480
F1000Res. 2017 May 26;6:748
pubmed: 28663787
J Leukoc Biol. 2018 Apr;103(4):629-641
pubmed: 29350874
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5640-4
pubmed: 10318937
J Clin Med. 2020 May 13;9(5):
pubmed: 32414131
Blood. 2013 May 2;121(18):3599-608
pubmed: 23487023
Autoimmun Rev. 2018 Feb;17(2):142-154
pubmed: 29180124
Blood. 2003 Apr 15;101(8):3052-7
pubmed: 12480696
Immunity. 2004 Jun;20(6):757-67
pubmed: 15189740
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
J Immunol. 2011 Jun 15;186(12):6753-61
pubmed: 21555534
Arthritis Res Ther. 2013 Jul 11;15(4):216
pubmed: 23856014
Cent Eur J Immunol. 2015;40(4):470-6
pubmed: 26862312
J Exp Med. 2008 Aug 4;205(8):1829-41
pubmed: 18606857
Nat Rev Immunol. 2012 Feb 17;12(3):191-200
pubmed: 22343568
Diabetes Res. 1991 Apr;16(4):171-5
pubmed: 1802483
J Immunol. 2008 Jan 15;180(2):850-7
pubmed: 18178824
Pediatr Diabetes. 2018 Aug;19(5):963-971
pubmed: 29527790
Int J Mol Sci. 2018 Mar 10;19(3):
pubmed: 29534427
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
An Pediatr (Barc). 2008 Jun;68(6):552-69
pubmed: 18559194
Diabetes Care. 2009 Aug;32(8):1384-90
pubmed: 19435955
J Exp Med. 2002 Feb 4;195(3):343-51
pubmed: 11828009
Immunity. 2009 Oct 16;31(4):654-64
pubmed: 19818653
Clin Exp Immunol. 2019 Oct;198(1):57-70
pubmed: 31116879
Islets. 2011 Jul-Aug;3(4):131-8
pubmed: 21606672
PLoS One. 2017 Aug 2;12(8):e0181134
pubmed: 28767726
J Immunol. 2004 Jan 15;172(2):937-42
pubmed: 14707066
Nat Immunol. 2002 Apr;3(4):373-82
pubmed: 11919579
J Cell Biol. 2018 Sep 3;217(9):3267-3283
pubmed: 29967280